218 related articles for article (PubMed ID: 1378153)
1. Can intravenous beta-blockade predict long-term hemodynamic benefit in chronic congestive heart failure secondary to ischemic heart disease? A comparison of intravenous with oral carvedilol.
DasGupta P; Lahiri A
J Cardiovasc Pharmacol; 1992; 19 Suppl 1():S62-7. PubMed ID: 1378153
[TBL] [Abstract][Full Text] [Related]
2. Can intravenous beta blockade predict long-term haemodynamic benefit in chronic congestive heart failure secondary to ischaemic heart disease? A comparison between intravenous and oral carvedilol.
DasGupta P; Lahiri A
Clin Investig; 1992; 70 Suppl 1():S98-104. PubMed ID: 1350492
[TBL] [Abstract][Full Text] [Related]
3. The effects of intravenous carvedilol, a new multiple action vasodilatory beta-blocker, in congestive heart failure.
DasGupta P; Broadhurst P; Lahiri A
J Cardiovasc Pharmacol; 1991; 18 Suppl 4():S12-6. PubMed ID: 1721973
[TBL] [Abstract][Full Text] [Related]
4. Value of carvedilol in congestive heart failure secondary to coronary artery disease.
Das Gupta P; Broadhurst P; Raftery EB; Lahiri A
Am J Cardiol; 1990 Nov; 66(15):1118-23. PubMed ID: 1977300
[TBL] [Abstract][Full Text] [Related]
5. Effects of carvedilol, a vasodilator-beta-blocker, in patients with congestive heart failure due to ischemic heart disease. Australia-New Zealand Heart Failure Research Collaborative Group.
Circulation; 1995 Jul; 92(2):212-8. PubMed ID: 7600653
[TBL] [Abstract][Full Text] [Related]
6. Differences between beta-blockers in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized crossover trial.
Jabbour A; Macdonald PS; Keogh AM; Kotlyar E; Mellemkjaer S; Coleman CF; Elsik M; Krum H; Hayward CS
J Am Coll Cardiol; 2010 Apr; 55(17):1780-7. PubMed ID: 20413026
[TBL] [Abstract][Full Text] [Related]
7. Impact of initiating carvedilol before angiotensin-converting enzyme inhibitor therapy on cardiac function in newly diagnosed heart failure.
Sliwa K; Norton GR; Kone N; Candy G; Kachope J; Woodiwiss AJ; Libhaber C; Sareli P; Essop R
J Am Coll Cardiol; 2004 Nov; 44(9):1825-30. PubMed ID: 15519014
[TBL] [Abstract][Full Text] [Related]
8. Carvedilol in hypertension: effects on hemodynamics and 24-hour blood pressure.
Lund-Johansen P; Omvik P; Nordrehaug JE; White W
J Cardiovasc Pharmacol; 1992; 19 Suppl 1():S27-34. PubMed ID: 1378146
[TBL] [Abstract][Full Text] [Related]
9. Changes in heart rate variability are correlated to hemodynamic improvement with chronic CARVEDILOL therapy in heart failure.
Bullinga JR; Alharethi R; Schram MS; Bristow MR; Gilbert EM
J Card Fail; 2005 Dec; 11(9):693-9. PubMed ID: 16360965
[TBL] [Abstract][Full Text] [Related]
10. Tolerability of beta-blockers in outpatients with refractory heart failure who were receiving continuous milrinone.
Earl GL; Verbos-Kazanas MA; Fitzpatrick JM; Narula J
Pharmacotherapy; 2007 May; 27(5):697-706. PubMed ID: 17461705
[TBL] [Abstract][Full Text] [Related]
11. Levosimendan versus dobutamine in heart failure patients treated chronically with carvedilol.
Duygu H; Turk U; Ozdogan O; Akyuz S; Kirilmaz B; Alioglu E; Gunduz R; Bozkaya YT; Turkoglu C; Payzin S
Cardiovasc Ther; 2008; 26(3):182-8. PubMed ID: 18786088
[TBL] [Abstract][Full Text] [Related]
12. Carvedilol improves left ventricular function and symptoms in chronic heart failure: a double-blind randomized study.
Olsen SL; Gilbert EM; Renlund DG; Taylor DO; Yanowitz FD; Bristow MR
J Am Coll Cardiol; 1995 May; 25(6):1225-31. PubMed ID: 7722114
[TBL] [Abstract][Full Text] [Related]
13. Exchange of beta-blockers in heart failure patients. Experiences from the poststudy phase of COMET (the Carvedilol or Metoprolol European Trial).
Di Lenarda A; Remme WJ; Charlesworth A; Cleland JG; Lutiger B; Metra M; Komajda M; Torp-Pedersen C; Scherhag A; Swedberg K; Poole-Wilson PA;
Eur J Heart Fail; 2005 Jun; 7(4):640-9. PubMed ID: 15921806
[TBL] [Abstract][Full Text] [Related]
14. Carvedilol, a new nonselective beta-blocker with intrinsic anti- Alpha1-adrenergic activity, has a greater portal hypotensive effect than propranolol in patients with cirrhosis.
Bañares R; Moitinho E; Piqueras B; Casado M; García-Pagán JC; de Diego A; Bosch J
Hepatology; 1999 Jul; 30(1):79-83. PubMed ID: 10385642
[TBL] [Abstract][Full Text] [Related]
15. Beta-blocker therapy influences the hemodynamic response to inotropic agents in patients with heart failure: a randomized comparison of dobutamine and enoximone before and after chronic treatment with metoprolol or carvedilol.
Metra M; Nodari S; D'Aloia A; Muneretto C; Robertson AD; Bristow MR; Dei Cas L
J Am Coll Cardiol; 2002 Oct; 40(7):1248-58. PubMed ID: 12383572
[TBL] [Abstract][Full Text] [Related]
16. Effects of carvedilol on heart rate and blood pressure variability in subjects with chronic heart failure.
Piccirillo G; Luparini RL; Celli V; Moisè A; Lionetti M; Marigliano V; Cacciafesta M
Am J Cardiol; 2000 Dec; 86(12):1392-5, A6. PubMed ID: 11113424
[TBL] [Abstract][Full Text] [Related]
17. Carvedilol: use in chronic heart failure.
Doughty RN; White HD
Expert Rev Cardiovasc Ther; 2007 Jan; 5(1):21-31. PubMed ID: 17187454
[TBL] [Abstract][Full Text] [Related]
18. Significance of combined angiotensin II receptor blocker and carvedilol therapy in patients with congestive heart failure and arginine variant.
Iwata A; Miura S; Nishikawa H; Kawamura A; Matsuo Y; Sako H; Kumagai K; Matsuo K; Saku K
J Cardiol; 2006 Jan; 47(1):1-7. PubMed ID: 16475467
[TBL] [Abstract][Full Text] [Related]
19. The effects of 2 beta-receptor blocking agents on the microcirculation of healthy subjects and of hypertensive patients.
Albrecht M; Haustein KO
Int J Clin Pharmacol Ther; 1997 Dec; 35(12):580-6. PubMed ID: 9455718
[TBL] [Abstract][Full Text] [Related]
20. Betaxolol versus carvedilol in chronic heart failure (BETACAR study). Rationale and design.
Böhler S; Saubadu S; Scheldewaert R; Figulla HR
Arzneimittelforschung; 1999 Apr; 49(4):311-7. PubMed ID: 10337449
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
